Drug Profile
RG 7112
Alternative Names: R 1772; R-7112; RG-7112; RO-5045337Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Roche
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto-oncogene protein c mdm2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Haematological malignancies; Liposarcoma; Soft tissue sarcoma; Solid tumours
Most Recent Events
- 26 Jun 2017 Roche completes a phase I trial in Haematological malignancies and Solid tumours in USA, Canada and France (NCT01677780)
- 30 Nov 2013 Roche completes a phase I trial in Acute myeloid leukaemia (combination therapy) in USA, Canada, France, Italy and the UK (NCT01635296)
- 25 Jul 2013 Discontinued - Phase-I for Acute myeloid leukaemia (combination therapy) in USA, Canada, France, Italy and United Kingdom (PO)